Know Cancer

forgot password

Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease

Phase 2
18 Years
Open (Enrolling)
Prostate Cancer

Thank you

Trial Information

Phase IIB, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of MPC-7869 in Delaying the Systemic Progression of Prostate Cancer in Patients With Intermediate to High Risk of Recurrence With Rising PSA Levels After Prostatectomy, Prostatectomy and Radiotherapy or Radiotherapy Alone for Localized Disease


- Determine the effect of R-flurbiprofen on time to systemic disease progression
evaluated over a minimum of 3 years in patients with localized adenocarcinoma of the
prostate with an intermediate or high risk of recurrence and rising prostate-specific
antigen (PSA) levels after radiotherapy alone, prostatectomy alone, or both
radiotherapy and prostatectomy.

- Determine the effect of this drug on the change in serum PSA levels over time prior to
androgen-deprivation therapy (ADT) in these patients.

- Determine the effect of this drug on the time of initiation of ADT in these patients.

- Determine the effect of this drug on the number of patients requiring ADT.

- Determine the safety of this drug in these patients.

- Determine the population pharmacokinetics of R-flurbiprofen and bioinversion of R-ToS
in this patient population.

- Determine the number of patients with systemic disease progression at the end of the

- Determine the time to clinical disease progression in patients treated with this drug.

- Determine the time to prostate cancer-related mortality and time to all cause mortality
in patients treated with this drug.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
are stratified according to risk of recurrence based on Gleason score at diagnosis (5-7 vs
8-10). Patients are randomized to 1 of 3 treatment arms.

- Arm I: Patients receive oral low-dose R-flurbiprofen twice daily.

- Arm II: Patients receive oral high-dose R-flurbiprofen twice daily.

- Arm III: Patients receive oral placebo twice daily. In all arms, treatment continues
for up to 5.5 years (66 months) in the absence of disease progression or unacceptable
toxicity. Patients who demonstrate increased prostate-specific antigen without
objective disease progression and require androgen-deprivation therapy (ADT) continue
receiving R-flurbiprofen. Patients who develop local recurrence or systemic disease may
withdraw from study and receive additional therapy off study.

PROJECTED ACCRUAL: Approximately 390 patients (130 per treatment arm) will be accrued for
this study within 3 years.

Inclusion Criteria


- Histologically confirmed localized adenocarcinoma of the prostate (from a
pre-operative core biopsy, surgical specimen, or post-therapy core biopsy)

- Gleason score 5-10 at diagnosis (the highest score is used if multiple scores are

- Must have undergone 1 of the following curative treatment strategies:

- Radical prostatectomy

- Not a candidate for radiotherapy

- Radical prostatectomy followed by radiotherapy at the time of surgery or any
time thereafter

- Radiotherapy of the prostate and/or surrounding structures by external beam
radiotherapy (EBRT), brachytherapy (BT), or a combination of EBRT and BT

- Must have 3 consecutive rising prostate-specific antigen (PSA) measurements OR meets
slope criteria

- Biochemical failure, meeting 1 of the following criteria:

- PSA at least 0.2 ng/mL post radical prostatectomy

- PSA greater than 1.5 ng/mL after radiotherapy or appropriate calculated slope

- Testosterone at least 100 ng/mL

- No rise in PSA with concurrent clinically active prostatitis

- No metastatic prostate cancer

- PSA no greater than 20.0 ng/mL



- 18 and over

Performance status

- Karnofsky 70-100%

Life expectancy

- Not specified


- WBC at least 2,500/mm^3

- Platelet count at least 100,000/mm^3

- Hemoglobin at least 10 g/dL


- Bilirubin no greater than 1.5 mg/dL

- AST or ALT no greater than 2 times upper limit of normal


- Creatinine no greater than 2.0 mg/dL


- No uncontrolled cardiac conditions

- No New York Heart Association class III or IV heart disease


- No active ulcer disease diagnosed within the past 3 months

- No upper gastrointestinal bleed requiring a transfusion within the past 3 years

- No non-steroidal anti-inflammatory drug (NSAID)-associated ulcers within the past 5


- No known hypersensitivity to NSAIDs, including COX-2-specific inhibitors (e.g.,
celecoxib or rofecoxib)

- No other malignancy within the past 5 years except basal cell or squamous cell skin

- No active systemic infections

- No other serious uncontrolled medical condition

- No dementia or altered mental status


Biologic therapy

- No concurrent biologic therapy


- More than 5 years since prior cytotoxic chemotherapy for other malignant disease

- No prior cytotoxic chemotherapy for prostate cancer

- No concurrent chemotherapy

Endocrine therapy

- More than 9 months since prior androgen-deprivation therapy other than as
cytoreductive therapy (neoadjuvantly or adjuvantly for less than 9 months) with the
intent to cure

- More than 3 months since prior cyproterone, finasteride, diethylstilbestrol,
megestrol, or other hormonally active (antiandrogen or antiprostate) therapies


- See Disease Characteristics

- No prior strontium chloride Sr 89, samarium Sm 153 lexidronam pentasodium, or other
radioisotope materials for palliative intent or metastasis intervention

- Concurrent iodine I 125 or palladium Pd 103 for primary brachytherapy with curative
intent allowed


- See Disease Characteristics

- More than 8 weeks since prior major surgery and recovered

- No prior orchiectomy


- More than 1 month since prior PC-SPES

- More than 1 month since prior investigational agents or devices (6 months for other
investigational therapy for prostate cancer)

- No prior bisphosphonates (e.g., pamidronate, alendronate, or clodronate) for
palliative intent or metastasis intervention

- At least 2 months since prior chronic non-steroidal anti-inflammatory drugs (NSAIDs),
including cyclooxygenase-2 (COX-2)-specific inhibitors (e.g., celecoxib or
rofecoxib), administered for more than 7 days per month

- No concurrent CYP2C9 inhibitor or substrates, including but not limited to the

- Phenytoin

- Fluvastatin

- Amiodarone

- Fluconazole

- Acenocoumarol

- Diclofenac

- No concurrent ketoconazole

- No concurrent antiretroviral therapy for HIV-positive patients

- Concurrent cardioprotective aspirin up to 100 mg once daily allowed

Type of Study:


Study Design:

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment

Principal Investigator

Sheron B. Bass, RN, MS

Investigator Affiliation:

Myrexis Inc.


United States: Federal Government

Study ID:




Start Date:

February 2002

Completion Date:

Related Keywords:

  • Prostate Cancer
  • adenocarcinoma of the prostate
  • recurrent prostate cancer
  • Prostatic Neoplasms
  • Recurrence



Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
Walter Reed Army Medical Center Washington, District of Columbia  20307-5000
Ireland Cancer Center Cleveland, Ohio  44106-5065
Rhode Island Hospital Providence, Rhode Island  02903
Mallinckrodt Institute of Radiology Saint Louis, Missouri  63110
Veterans Affairs Medical Center - Albany Albany, New York  12208
University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin  53792
Charles M. Barrett Cancer Center at University Hospital Cincinnati, Ohio  45267-0526
Evanston Northwestern Health Care - Evanston Hospital Evanston, Illinois  60201
Loma Linda University Cancer Institute at Loma Linda University Medical Center Loma Linda, California  92354
21st Century Oncology - Fort Myers Fort Myers, Florida  33901-8082
Cancer Center at Lexington Clinic Lexington, Kentucky  40504
St. Agnes Cancer Center Baltimore, Maryland  21229
Vermont Cancer Center at University of Vermont Burlington, Vermont  05405-0075
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas Dallas, Texas  75390-9063
Center for Cancer Prevention and Care at Scott and White Clinic Temple, Texas  76508
Baylor University Medical Center Dallas, Texas  75246
Decatur Memorial Hospital Cancer Care Institute Decatur, Illinois  62526
Urology Associates of North Texas Arlington, Texas  76015
Urology Clinics of North Texas Dallas, Texas  75231
Lynn Regional Cancer Center West Boca Raton, Florida  33428
South Florida Medical Research Aventura, Florida  33180
North Idaho Urology Couer D'Alene, Idaho  83814
San Diego Urological Medical Group San Diego, California  92101
Lakeside Urology, P.C. St. Joseph, Michigan  49085-2521
Center for Urologic Care West Reading, Pennsylvania  19611
Urology Consultants, P.A. San Antonio, Texas  78229
Alaska Clinical Research Center, LLC Anchorage, Alaska  99508
AccuMed Research Associates Garden City, New York  11530
Urology Centers Of Alabama Homewood,, Alabama  35205
Oregon Urology Specialists Eugene, Oregon  97401
Urology Associates Nashville, Tennessee  37209
Salt Lake Research Salt Lake City, Utah  84124
Urology Associates Of Central California Fresno, California  93720
Orange County Urology Associates Laguna Hills, California  92653
South Orange County Hematology-Oncology Associates Laguna Hills, California  92653
Atlantic Urology Medical Group Long Beach, California  90806
Coastal Medical Research Group, Incorporated San Luis Obispo, California  93401
Urology Associates - Research Denver, Colorado  80210
UroSearch - Ocala Ocala, Florida  34471
Rice, Lake and Harper Urology, LLC Columbus, Georgia  31904
Cancer Care Specialists of Central Illinois, S.C. - Decatur Decatur, Illinois  62526
Northeast Indiana Research, LLC Fort Wayne, Indiana  46825-1675
Regional Urology, L.L.C. Shreveport, Louisiana  71101
Drs. Werner, Murdock and Francis, P.A., Urology Associates Greenbelt, Maryland  20770
Las Vegas, Nevada  89109
Lawrenceville Urology Lawrenceville, New Jersey  08648
Center for Urologic Care Voorhees, New Jersey  08043
Staten Island Urologic Oncology Staten Island, New York  10305
Urology Center Greensboro, North Carolina  27401
Urological Associates, Incorporated Columbus, Ohio  43222
Urological Associates of Lancaster, Ltd. Lancaster, Pennsylvania  17604
Center of Urologic Care of Berks County West Reading, Pennsylvania  19611
University Urological Research Institute Providence, Rhode Island  02904
Grand Strand Urology LLP Myrtle Beach, South Carolina  29572
University of Tennessee - Graduate School of Medicine Knoxville, Tennessee  37920
Highline Hospital Campus Seattle, Washington  98166
Northwest Hospital and Medical Center Seattle, Washington  98133